New Skin Cancer Drug Zolinza Approved

Posted: October 24, 2006

page 2 of 3

Benefits and Risks

The safety and effectiveness of Zolinza were evaluated in two clinical trials involving 107 people with CTCL, who received the drug after their disease came back or other treatments had failed.

Of patients receiving the drug, 30% saw improvement, with the benefit lasting an average of 168 days.

The most common serious side effects of Zolinza were blood clots in the lungs (pulmonary embolism), dehydration, deep vein thrombosis (blood clots in deep veins) and anemia.

Other side effects included diarrhea, nausea, anorexia, vomiting, constipation, fatigue, chills, and taste disorders.